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OBJECTIVE: Evidence concerning the relationship between
medical-care costs and tumor histology among advanced-staged
NSCLC patients is lacking. The purpose of this analysis was to
identify costs associated with ﬁrst-line chemotherapy treatment
and total lifetime medical-care costs by tumor histology among
elderly Stage IIIB/IV NSCLC patients treated with commonly
used doublet chemotherapy regimens. METHODS: Study
patients included those aged 65 years and older who were diag-
nosed with Stage IIIB/IV NSCLC in a SEER cancer registry
between 1997 and 2002 and who received ﬁrst-line treatment
with a commonly used doublet regimen. Study patients were
followed in the SEER-Medicare database to evaluate costs while
on ﬁrst-line chemotherapy treatment as well as lifetime medical-
care costs by histology for commonly used doublets. Pairwise
comparisons of costs estimated using non-parametric bootstrap
methodology were generated for treatment comparisons. Esti-
mated differences in mean costs, adjusted for sex, race age,
urban/rural, geographic region, stage, Charlson comorbidity
index and tumor histology are presented. RESULTS: Total life-
time medical-care costs for elderly IIIB/IV patients with squa-
mous cell carcinoma were $51,360, while costs for those with
non-squamous cell carcinoma were $50,905. Costs per month
were $6364 and $6870 respectively, and were dominated by
hospital and physician utilization. Among commonly used dou-
blets, the estimated difference in adjusted mean total costs for
Cisplatin/Carboplatin (P) and a Taxane (T) were signiﬁcantly
higher when compared to P and Gemcitabine (G) (difference
$4816 [$1554–$8101]). Similar ﬁndings were observed for costs
while on ﬁrst-line therapy, (difference $5686 [3738-$7630]
respectively). CONCLUSION: While lifetime medical-care costs
and costs while on ﬁrst-line chemotherapy among treated Stage
IIIB/IV NSCLC patients are substantial, the cost differential
between squamous cell and non-squamous cell carcinoma is
small. Controlling for tumor histology and other factors, patients
treated with a combined platinum and taxane regimen experi-
ence the highest costs.
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OBJECTIVE: Platinum-based chemotherapies have been associ-
ated with debilitating treatment-related complications among
patients with advanced squamous cell carcinoma of the head and
neck (ASCCHN). This study evaluated the incidence and costs of
such complications among ASCCHN patients undergoing radio-
therapy alone versus platinum-based chemoradiotherapy.
METHODS: Using 2000–2006 data from the PharMetrics
Patient-centric Database, this retrospective cohort study mea-
sured clinical practices, incidence rates, and costs of treatment-
related complications including oral complications, dehydration,
infection/fever, fatigue, malnutrition, nausea, neutropenia and
anemia among ASCCHN patients undergoing radiotherapy
alone or platinum-based chemoradiotherapy. Patients were iden-
tiﬁed if they had a SCCHN claim between June 30, 2000 and
December 31, 2005 and an indication of a secondary malignant
neoplasm (both based on ICD-9-CM diagnosis codes). Patients
were assigned to a treatment-based cohort–radiotherapy only or
platinum-based chemo-radiotherapy, and were followed for six
months. RESULTS: We identiﬁed 131 ASCCHN patients treated
with radiotherapy alone and 90 patients treated with chemora-
diotherapy, including 62 with cisplatin plus radiotherapy, 30
with carboplatin plus radiotherapy, and two with cisplatin and
carboplatin plus radiotherapy. Patients undergoing chemo-
radiotherapy were slightly younger than radiotherapy patients
(mean ages: 54.1 and 56.1 years, respectively), were more likely
to be male, and were less healthy, as evidenced by higher
Charlson co-morbidity scores. We found signiﬁcantly (P < 0.001)
higher rates of treatment-related complications among patients
receiving chemo-radiotherapy (87%) compared with patients
receiving only radiotherapy (51%). Mean per-patient costs asso-
ciated with treatment-related complications were $10,632 higher
among chemo-radiotherapy patients compared to radiotherapy
patients (P = 0.002). These costs comprised 18% of total costs
during follow-up for chemo-radiotherapy patients and 9% of
costs for radiotherapy patients. The most expensive complica-
tions were dehydration/electrolyte imbalance and oral complica-
tions. CONCLUSION: Our ﬁndings suggest that the excess
incidence and costs of treatment-related complications associated
with chemo-radiotherapy in ASCCHN are substantial. The emer-
gence of safer treatments may alleviate this cost burden.
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OBJECTIVE: To estimate mean costs per event of the most
common adverse events (AEs) due to treatment of non-small cell
lung cancer (NSCLC) in Mexican patients based on treatment
patterns (TP) and resource utilization. METHODS: Specialists
were invited to participate in a Modiﬁed Delphi Panel to
acknowledge real TP of AEs for patients undergoing NSCLC
treatment such as neutropenia (NP), anemia (AN), thrombocy-
topenia (TC), febrile neutropenia (FN), dyspnea (DS), hypersen-
sitivity (HS), rash (RA), nausea (NS), vomiting (VO), diarrhea
(DR), stomatitis (ST), peripheral neuromotor alterations (PNA),
anorexia (AX) and interstitial lung disease (ILD). Questionnaire
was designed based on experts’ opinion and answered by spe-
cialists, using a nine level Likert scale in order to obtain consen-
sus for the proposed scenarios. Scenarios included drugs use,
percentage of hospitalized patients, hospitalization days and visit
to emergency room, and laboratory/cabinet exams. Afterwards,
an analysis and controlled feedback with a moderated debate
stage took place until consensus achievement (7 approval-
median) for each questionnaire item. Economic analysis was
done under the public sector perspective. Unitary costs were
obtained from the Mexican Institute of Social Security (Diario
Abstracts A67
Oﬁcial de la Federación, 23-04-07). Results are expressed as AE
or its treatment cost in US dollars. RESULTS: Eight oncologists
participated in the Panel. Consensus was achieved for all items
after the questionnaire’s second ﬁlling round. Second line treat-
ment for NSCLC cost estimate was $5377.46 (includes four
chemotherapy cycles with docetaxel, administration costs and
premedication costs). Estimated cost for AEs per event was: RA
$112.13, AN $140.50, NS $194.56, VO $243.08, DR $243.64,
HS $251.56, NP $495.27, TC $948.00, PNA $1167.02, DS
$1807.86, AX $1939.88, ST $2055.82, FN $2527.39, and ILD
$5189.02. CONCLUSION: ILD was the most expensive AE due
to NSCLC treatment, while the most costly were those incurring
in emergency room visits and/or patient hospitalization.
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OBJECTIVE: Non-melanoma skin cancer incidence is increasing
yet no speciﬁc guidelines for treatment selection exist. Reports
vary on surgical treatment efﬁcacy, and treatment choice may be
based in-part on costs, despite little comparative cost informa-
tion. We compared 2007 treatment costs of the three most
common nonmelanoma skin cancer treatments: tumor destruc-
tion by ED&C, excision, and histologically-guided serial excision
(Mohs surgery). METHODS: We studied 936 consecutive non-
melanoma skin cancers diagnosed in 1999–2000 in a university-
afﬁliated dermatology practice. Clinical and utilization data were
obtained from patient surveys and medical records. We deter-
mined cost of treatments, repairs, pathology, and biopsies based
on size, lesion location, number of Mohs stages, medications,
and physician visits, using CPT codes and Medicare fees. We
controlled for procedure risk-selection factors in our sample.
RESULTS: A total of 27.2% of lesions were treated with ED&C,
29.2% with excision, and 43.6% with Mohs surgery. The
weighted average costs per lesion for initial treatment for ED&C,
excision, and Mohs were $221, $529, and $1287, respectively.
When wound repairs, pathology, drug costs and follow-up
physician visits were included, costs rose to $646, $1531, and
$2805. When controlling for risk selection using Mohs sample
for baseline risk, initial costs changed little ($232, $578, $1287).
However, when adding all costs to the controlled sample, the
totals rose to $1750, $2096, and $2805, and differences across
treatments diminished. The uncontrolled costs of Mohs proce-
dure itself (46%) accounts for a greater percentage of total costs
compared with the other two procedures (35%, 34%), and more
than subsequent repair costs (31%, 20% 2%). CONCLUSION:
Mohs surgery was the most costly procedure, however cost dif-
ferences across treatments diminished when controlling for treat-
ment selection factors. This is the ﬁrst cost study which compares
surgical treatment costs using the new (2007) Medicare/CPT
costing rules allowing higher payments for increased complexity
of lesion location.
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OBJECTIVE: To assess the impact of the human immunodeﬁ-
ciency virus (HIV) on the pathogenesis of human papillomavirus
(HPV) infection, precancerous lesions, invasive cervical cancer,
and total treatment costs in South African women. Invasive
cervical cancer is the second most common cancer among South
African women. The high prevalence of HIV in South Africa
(18%) is likely a contributing factor to the high rates of cervical
cancer, as immunocompromised patients are at higher risk of
HPV infection and associated precancerous lesions. METHODS:
We developed a lifetime Markov simulation model of the natural
history of cervical neoplasia and HIV infection. The model was
used to predict the impact of HIV and acquired immunodeﬁ-
ciency syndrome (AIDS)-related mortality on the course of cer-
vical disease in a hypothetical cohort of 100,000 South African
women. Clinical data were based on published South African
literature, high-quality clinical studies, and expert opinion. Risk
of progression of HIV/AIDS was based on CD4 cell counts and
viral load levels. Primary outcome measures included lifetime
risk of cervical intraepithelial neoplasia and cervical cancer, years
of life saved, quality-adjusted life years saved (QALYs), and total
lifetime costs. RESULTS: Lifetime risk of cervical cancer ranged
from 2.3% among HIV-negative women to 3.3% in HIV-positive
women. In a cohort of 100,000 women, the high rate of HIV
infection in South Africa led to an additional 5200 HPV infec-
tions, 490 cervical cancers, and 175 cervical cancer deaths. HIV
infection decreased average life expectancy among South African
women by 3.31 years or 3.28 QALYs and increased costs by
approximately Rand 21,400 per woman. CONCLUSION: HIV
infection contributes to higher rates of invasive cervical cancer
and increases costs. Given the high prevalence of HIV infection in
South Africa, more frequent cervical cancer screening for HIV-
positive women may be warranted.
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OBJECTIVE: The few workloss studies of prostate cancer
patients are short-term and single-treatment focused. We
compare long-term patterns of workloss and costs of 5414 newly
diagnosed patients over 10 years stratiﬁed by treatment type, age
and risk group. METHODS: Workloss patterns for prostate
cancer were identiﬁed using CaPSURE, a national disease registry
that includes clinical data and patient-reported outcome ques-
tionnaires, including demographics, co-morbidity, risk, and work
patterns at 31 academic and community urology practices. Both
change in work status (decreased if changed from full to part-
time or disability, increased if changed back to full time, or no
change) and hours lost were assessed at six-month intervals over
ten years. National hourly wages were used to determine work-
loss costs by age, disease risk, and treatment type. RESULTS:
Patients reported average weekly work reductions of 15.7 hours
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